Celiac Wire

Pipeline

Treatments beyond the gluten-free diet

Several approaches have reached randomised trials. None has replaced the diet, and the field has a long history of promising results that did not hold.

Updated 3 min read 16 citations Evidence strength 3/5

Why a drug is hard

Coeliac disease has an unusual property among autoimmune conditions: the trigger is known and removable. That sets a very high bar — any drug must be safer and more convenient than simply not eating gluten, in a population that is not acutely ill once treated. It also means the realistic target is not "eat bread again" but "be protected when the restaurant gets it wrong".

Transglutaminase 2 inhibition

Tissue transglutaminase modifies gluten peptides in a way that makes them far more immunogenic — it is the enzyme at the centre of the disease mechanism and the target of the antibody used to diagnose it. Blocking it is therefore mechanistically elegant. A randomised trial of a TG2 inhibitor reported attenuation of gluten-induced mucosal injury during challenge [5], which is the most encouraging single result the field has produced.

TG2 inhibition

Enzymatic degradation

Glutenases aim to break gluten down in the stomach before it reaches the small intestine. The engineering problem is severity: to protect against a normal wheat meal an enzyme must degrade grams of protein in a hostile acidic environment within a short window. Several candidates have shown activity against small quantities without demonstrating protection against realistic exposure. Work on probiotic preparations with in vivo gluten-degrading activity illustrates the approach.

Probiotics

A systematic review and meta-analysis of randomised controlled trials of probiotics for coeliac disease exists and does not support routine use. Microbiome differences in coeliac disease are real and reproducible, but modifying them has not translated into clinical benefit.

Other directions

  • Immune tolerance induction. Peptide-based approaches aiming to retrain the immune response, conceptually similar to allergen immunotherapy.
  • Tight junction modulation. Reducing intestinal permeability so fewer gluten peptides cross. Trials have been mixed.
  • Cytokine blockade. Aimed at refractory disease rather than at ordinary coeliac disease [7].
  • Vaccination. Long-discussed, repeatedly delayed, and not close.

What to expect

The plausible next step is an adjunct that reduces the consequences of accidental exposure for people who are already strict. That would be genuinely valuable — inadvertent exposure is common, as the contamination research shows — without being the freedom the coverage tends to promise.

Common questions

Will there be a pill that lets me eat bread?
Not on current evidence. The trials target protection against contamination, not resumption of a normal diet.
Should I take a gluten-digesting enzyme?
They have not been shown to protect against meal-sized gluten exposure, and relying on one is risky.
Are probiotics worth trying?
Meta-analysis of randomised trials does not support them for coeliac disease specifically.
How would I join a trial?
National coeliac societies and clinical trial registries list recruiting studies; your gastroenterologist can advise on eligibility.

References

Every citation below links to the original peer-reviewed record on PubMed or via DOI. Nothing here is a substitute for medical advice.

  1. European Society for the Study of Coeliac Disease 2025 Updated Guidelines on the Diagnosis and Management of Coeliac Disease in Adults. Part 1: Diagnostic Approach Al-Toma A, Zingone F, Branchi F, et al. · United European gastroenterology journal · 2025 · Clinical guideline DOIPubMed 40999951Full text
  2. Updated joint ESPGHAN/NASPGHAN guidelines for management of Helicobacter pylori infection in children and adolescents (2023) Homan M, Jones NL, Bontems P, et al. · Journal of pediatric gastroenterology and nutrition · 2024 · Clinical guideline DOIPubMed 39148213
  3. ACG Clinical Guideline: Management of Irritable Bowel Syndrome Lacy BE, Pimentel M, Brenner DM, et al. · The American journal of gastroenterology · 2021 · Clinical guideline DOIPubMed 33315591
  4. European Society for the Study of Coeliac Disease (ESsCD) guideline for coeliac disease and other gluten-related disorders Al-Toma A, Volta U, Auricchio R, et al. · United European gastroenterology journal · 2019 · Clinical guideline DOIPubMed 31210940Full text
  5. ACG clinical guidelines: diagnosis and management of celiac disease Rubio-Tapia A, Hill ID, Kelly CP, et al. · The American journal of gastroenterology · 2013 · Clinical guideline DOIPubMed 23609613Full text
  6. A Randomized Trial of a Transglutaminase 2 Inhibitor for Celiac Disease Schuppan D, Mäki M, Lundin KEA, et al. · The New England journal of medicine · 2021 · Randomised controlled trial DOIPubMed 34192430
  7. Rotavirus Infections: Pathophysiology, Symptoms, and Vaccination Pawłuszkiewicz K, Ryglowski PJ, Idzik N, et al. · Pathogens (Basel, Switzerland) · 2025 · Review DOIPubMed 40430800Full text
  8. AGA Clinical Practice Update on Management of Iron Deficiency Anemia: Expert Review DeLoughery TG, Jackson CS, Ko CW, et al. · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2024 · Review DOIPubMed 38864796
  9. Advances in Nonresponsive and Refractory Celiac Disease Malamut G, Soderquist CR, Bhagat G, et al. · Gastroenterology · 2024 · Review DOIPubMed 38556189
  10. AGA Clinical Practice Update on Evaluation and Management of Belching, Abdominal Bloating, and Distention: Expert Review Moshiree B, Drossman D, Shaukat A · Gastroenterology · 2023 · Review DOIPubMed 37452811
  11. AGA Clinical Practice Update on Management of Refractory Celiac Disease: Expert Review Green PHR, Paski S, Ko CW, et al. · Gastroenterology · 2022 · Review DOIPubMed 36137844
  12. Celiac disease and bone Kondapalli AV, Walker MD · Archives of endocrinology and metabolism · 2022 · Review DOIPubMed 36382765Full text
  13. Epidemiology of Non-Hodgkin's Lymphoma Thandra KC, Barsouk A, Saginala K, et al. · Medical sciences (Basel, Switzerland) · 2021 · Review DOIPubMed 33573146Full text
  14. Small and Large Intestine (I): Malabsorption of Nutrients Montoro-Huguet MA, Belloc B, Domínguez-Cajal M · Nutrients · 2021 · Review DOIPubMed 33920345Full text
  15. Medical Care of Adults With Down Syndrome: A Clinical Guideline Tsou AY, Bulova P, Capone G, et al. · JAMA · 2020 · Review DOIPubMed 33079159
  16. Celiac disease Rodrigo L · World journal of gastroenterology · 2006 · Review DOIPubMed 17075969Full text